President Bush's choice to head the FDA is refusing to give Congress all the information it seeks about the controversial antibiotic Ketek, setting up further confrontations with Sen. Charles Grassley, R-Ia., who is blocking his nomination. The acting FDA chief says full disclosure of the information about Ketek could have a chilling effect on the agency's ability to be an independent evaluator of drug safety issues. Ketek has been linked to severe liver problems and several deaths.
December 04, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
President Bush’s choice to head the Food and Drug Administration is refusing to give Congress all the information it seeks about a controversial antibiotic, setting up further confrontations with a Republican senator blocking his nomination.
The agency’s acting chief, Dr. Andrew von Eschenbach, said full disclosure of the information about Ketek could have a chilling effect on the FDA’s ability to be an independent and objective evaluator of drug safety and other issues.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
Exciting Career Opportunities at Nuzzo & Roberts! Nuzzo & Roberts, a leading mid-sized insurance defense firm based in Cheshire, CT...
